The profits of GlaxoSmithKline increased by a 41.21-fold in the first half (1H) of 2022, reaching EGP 871.8m, compared to 1H 2021’s EGP 20.65m.
Moreover, the company’s total sales increased to EGP 716.78m, compared to EGP 406.84m.
Previously, GlaxoSmithKline appointed Dylan Jackson as Chairperson of the Board of Directors and Mohamed Al-Dababy as its Managing Director and CEO in Egypt.
Al-Dababy expressed his pride in the trust GlaxoSmithKline has put in him, describing the entity as a “multinational corporate with a strong Egyptian flavour.”
He also said that it is committed to enhancing health care for Egyptians in all areas, especially by focusing on three main business units, including primary care, respiratory care, and specialised products, adding that GlaxoSmithKline plays a key role in helping millions of people in an attempt to achieve the core mission of bringing science, talent, and technology together to fight diseases.
“In Egypt, we have two manufacturing facilities that provide the latest products along with a large and growing range of products that we provide to the Egyptian market through our global supply chain. In my new role, I look forward to helping GlaxoSmithKline serve Egyptian society.”
“It is a target we aim to achieve by utilising our capable and skilled workforce. We will work with all stakeholders to support national efforts to strengthen the health care sector in Egypt in general and implement a comprehensive health care system in particular under the leadership of the Egyptian government, which is making tremendous efforts in this regard,” he concluded.
